| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911157 | Lung Cancer | 2014 | 9 Pages |
Abstract
Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Liang Shi, Junfang Tang, Li Tong, Zhe Liu,